Medicines Co, Alnylam generate positive buzz with evidence of a durable, 6-month LDL response to PCSK9 rival
The Medicines Company $MDCO and its partner Alnylam $ALNY posted an impressive set of 6-month results for the first batch of patients to reach the annual halfway mark on their new and perhaps much easier PCSK9 drug regimen. A single 300 mg injection of their RNAi drug — now dubbed inclisiran — registered a mean 43% reduction in bad LDL cholesterol after 180 days, triggering some excited buzz among the analysts following this program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
